Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Page 1
Dyspnea-induced Limitation (DYSLIM), a new self-administered concise questionnaire to evaluate dyspnea-related activity limitation in chronic respiratory diseases.
Perez T, Roche N, Nunes H, Burgel PR, Chaouat A, Surpas P, Herengt F, Garcia G, Grosbois JM, Stelianides S, de Rigal P, Guérin P, Arnould B, Coste J. Perez T, et al. Among authors: burgel pr. Respir Med. 2023 Oct;217:107309. doi: 10.1016/j.rmed.2023.107309. Epub 2023 Jun 30. Respir Med. 2023. PMID: 37394196
Responsiveness was evaluated by post-pulmonary rehabilitation data in 52 COPD patients. RESULTS: Acceptability was high and short term (7 days) reproducibility was satisfactory (Kappa mostly above 0.7). ...
Responsiveness was evaluated by post-pulmonary rehabilitation data in 52 COPD patients. RESULTS: Acceptability was high and short term …
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations.
Szczesniak R, Andrinopoulou ER, Su W, Afonso PM, Burgel PR, Cromwell E, Gecili E, Ghulam E, Goss CH, Mayer-Hamblett N, Keogh RH, Liou TG, Marshall B, Morgan WJ, Ostrenga JS, Pasta DJ, Stanojevic S, Wainwright C, Zhou GC, Fernandez G, Fink AK, Schechter MS. Szczesniak R, et al. Among authors: burgel pr. Ann Am Thorac Soc. 2023 Jul;20(7):958-968. doi: 10.1513/AnnalsATS.202209-829OC. Ann Am Thorac Soc. 2023. PMID: 36884219
Marginal models consistently estimated less rapid lung function decline than mixed-effects models across scenarios, except for short-term follow-up (both were 1.4). Rate of decline estimates from nonlinear models diverged by age 30. ...Conclusions: Differences were as high …
Marginal models consistently estimated less rapid lung function decline than mixed-effects models across scenarios, except for short-term …
2022 Update of indications and contraindications for lung transplantation in France.
Le Pavec J, Pison C, Hirschi S, Bunel V, Mordant P, Brugière O, Guen ML, Olland A, Coiffard B, Renaud-Picard B, Tissot A, Brioude G, Borie R, Crestani B, Deslée G, Stelianides S, Mal H, Schuller A, Falque L, Lorillon G, Tazi A, Burgel PR, Grenet D, De Miranda S, Bergeron A, Launay D, Cottin V, Nunes H, Valeyre D, Uzunhan Y, Prévot G, Sitbon O, Montani D, Savale L, Humbert M, Fadel E, Mercier O, Mornex JF, Dauriat G, Reynaud-Gaubert M. Le Pavec J, et al. Among authors: burgel pr. Respir Med Res. 2023 Jun;83:100981. doi: 10.1016/j.resmer.2022.100981. Epub 2022 Nov 28. Respir Med Res. 2023. PMID: 36565563
The considerable developments have been driven over the years by indefatigable work conducted at LTx centers to improve donor and recipient selection, combined with multifaceted efforts to overcome challenges raised by the surgical procedure, perioperative care, and long-term …
The considerable developments have been driven over the years by indefatigable work conducted at LTx centers to improve donor and recipient …
[Updated indications and contraindications in 2022 for lung transplantation in France].
Le Pavec J, Pison C, Hirschi S, Bunel V, Mordant P, Brugière O, Le Guen M, Olland A, Coiffard B, Renaud-Picard B, Tissot A, Brioude G, Borie R, Crestani B, Deslée G, Stelianides S, Mal H, Schuller A, Falque L, Lorillon G, Tazi A, Burgel PR, Grenet D, De Miranda S, Bergeron A, Launay D, Cottin V, Nunes H, Valeyre D, Uzunhan Y, Prévot G, Sitbon O, Montani D, Savale L, Humbert M, Fadel E, Mercier O, Mornex JF, Dauriat G, Reynaud-Gaubert M. Le Pavec J, et al. Among authors: burgel pr. Rev Mal Respir. 2022 Dec;39(10):855-872. doi: 10.1016/j.rmr.2022.10.005. Epub 2022 Nov 10. Rev Mal Respir. 2022. PMID: 36372607 Review. French.
Major developments have been impelled over the years by painstaking efforts at LTx centers to improve donor and recipient selection, and multifaceted attempts have been made to meet the challenges raised by surgical management, perioperative care, and long-term medical com …
Major developments have been impelled over the years by painstaking efforts at LTx centers to improve donor and recipient selection, and mul …
CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France.
Regard L, Martin C, Burnet E, Da Silva J, Burgel PR. Regard L, et al. Among authors: burgel pr. Cells. 2022 May 28;11(11):1769. doi: 10.3390/cells11111769. Cells. 2022. PMID: 35681464 Free PMC article. Review.
Their clinical efficacy has been demonstrated in phase 3 clinical trials, particularly in terms of lung function and pulmonary exacerbations, nutritional status, and quality of life in people with gating mutations (ivacaftor), homozygous for the F508del mutation (lumacaftor/ivaca …
Their clinical efficacy has been demonstrated in phase 3 clinical trials, particularly in terms of lung function and pulmonary exacerbations …
Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome.
Pailhoriès H, Herrmann JL, Velo-Suarez L, Lamoureux C, Beauruelle C, Burgel PR, Héry-Arnaud G. Pailhoriès H, et al. Among authors: burgel pr. Eur Respir Rev. 2022 May 25;31(164):210259. doi: 10.1183/16000617.0259-2021. Print 2022 Jun 30. Eur Respir Rev. 2022. PMID: 35613743 Free PMC article. Review.
Chronic respiratory diseases (CRDs) such as cystic fibrosis, severe asthma, chronic obstructive pulmonary disease and bronchiectasis, managed with long-term antibiotic therapies, lead to multidrug resistance. Antibiotic susceptibility testing provides a partial view of the …
Chronic respiratory diseases (CRDs) such as cystic fibrosis, severe asthma, chronic obstructive pulmonary disease and bronchiectasis, manage …
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis.
Martin C, Reynaud-Gaubert M, Hamidfar R, Durieu I, Murris-Espin M, Danner-Boucher I, Chiron R, Leroy S, Douvry B, Grenet D, Mely L, Ramel S, Montcouquiol S, Lemonnier L, Burnet E, Paillasseur JL, Da Silva J, Burgel PR. Martin C, et al. Among authors: burgel pr. J Cyst Fibros. 2022 May;21(3):489-496. doi: 10.1016/j.jcf.2022.01.012. Epub 2022 Feb 2. J Cyst Fibros. 2022. PMID: 35123901
BACKGROUND: Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients with cystic fibrosis (CF) and advanced pulmonary disease, often leading to suspend the indication for lung transplantation. Yet no long-term data is available in lung transplant can …
BACKGROUND: Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients with cystic fibrosis (CF) and advanced pulmonary …
COVID-19 outcomes in people with cystic fibrosis.
Burgel PR, Goss C. Burgel PR, et al. Curr Opin Pulm Med. 2021 Nov 1;27(6):538-543. doi: 10.1097/MCP.0000000000000823. Curr Opin Pulm Med. 2021. PMID: 34620788 Free PMC article. Review.
Vaccination appears important to all PwCF, with special priority on developing adequate vaccination scheme for transplant recipients. Long-term effects of COVID-19 on the CF population remains unknown. SUMMARY: The COVID-19 pandemic has caused significant impacts on PwCF a …
Vaccination appears important to all PwCF, with special priority on developing adequate vaccination scheme for transplant recipients. Long- …
Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
Martin C, Burnet E, Ronayette-Preira A, de Carli P, Martin J, Delmas L, Prieur B, Burgel PR. Martin C, et al. Among authors: burgel pr. Respir Med Res. 2021 Nov;80:100829. doi: 10.1016/j.resmer.2021.100829. Epub 2021 May 17. Respir Med Res. 2021. PMID: 34091202
The majority of patients contrasted treatment burden, symptom severity, depression and a closed future marked by death or transplantation before elexacaftor-tezacaftor-ivacaftor, to renewed and unexpected physical strength, leading to greater self-confidence, autonomy and long- …
The majority of patients contrasted treatment burden, symptom severity, depression and a closed future marked by death or transplantation be …
Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension.
Le Ribeuz H, To L, Ghigna MR, Martin C, Nagaraj C, Dreano E, Rucker-Martin C, Girerd B, Bouligand J, Pechoux C, Lambert M, Boet A, Issard J, Mercier O, Hoetzenecker K, Manoury B, Becq F, Burgel PR, Cottart CH, Olschewski A, Sermet-Gaudelus I, Perros F, Humbert M, Montani D, Antigny F. Le Ribeuz H, et al. Among authors: burgel pr. Eur Respir J. 2021 Nov 25;58(5):2000653. doi: 10.1183/13993003.00653-2020. Print 2021 Nov. Eur Respir J. 2021. PMID: 33926975 Free article.
CFTR-mediated pulmonary artery relaxation was reduced in pulmonary arteries from iPAH patients and rats with monocrotaline- or chronic hypoxia-induced PH. Long-term in vivo CFTR inhibition in rats significantly increased right ventricular systolic pressure, which was relat …
CFTR-mediated pulmonary artery relaxation was reduced in pulmonary arteries from iPAH patients and rats with monocrotaline- or chronic hypox …
27 results